Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;169(3):384-387.
doi: 10.1111/imm.13656. Epub 2023 May 15.

Prevalence of salivary anti-SARS-CoV-2 IgG antibodies in vaccinated children

María Noel Badano  1   2 , Alejandra Duarte  1 , Gabriela Salamone  1 , Florencia Sabbione  1 , Matias Pereson  3 , Roberto Chuit  4 , Patricia Baré  1   2
Affiliations
Free article

Prevalence of salivary anti-SARS-CoV-2 IgG antibodies in vaccinated children

María Noel Badano et al. Immunology. 2023 Jul.
Free article
No abstract available

Keywords: antibodies; mucosal immunology; vaccination; viral.

PubMed Disclaimer

References

REFERENCES

    1. Ketas TJ, Chaturbhuj D, Portillo VMC, Francomano E, Golden E, Chandrasekhar S, et al. Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva. Pathog Immun. 2021;6(1):116-34. https://doi.org/10.20411/pai.v6i1.441
    1. Healy K, Pin E, Chen P, Söderdahl G, Nowak P, Mielke S, et al. Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals. Med (N Y). 2022;3(2):137-153.e3. https://doi.org/10.1016/j.medj.2022.01.001
    1. Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2022;386(1):35-46. https://doi.org/10.1056/NEJMoa2116298
    1. Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239-50. https://doi.org/10.1056/NEJMoa2107456
    1. Xia S, Zhang Y, Wang Y, Wang H, Yang YK, Gao GF, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. Lancet Infect Dis. 2022;22(2):196-208. https://doi.org/10.1016/S1473-3099(21)00462-X

Substances

LinkOut - more resources